Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9-year zoledronic acid extension study in postmenopausal osteoporosis
2007-005383-27Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis and osteoporosis comparing Continued zoledronic acid to Year 9 with Zoledronic acid for 6 years followed by placebo for 3 years (2 arms). Started Jul 2008; status: completed.
02
Drugs
zoledronic acid
03
Conditions
postmenopausal osteoporosisosteoporosis
Beyond the preview
Go deeper on 2007-005383-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005383-27.